Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Dimai, HP; Pietschmann, P; Resch, H; Preisinger, E; Fahrleitner-Pammer, A; Dobnig, H; Klaushofer, K; Austrian Society for Bone and Mineral Research (AuSBMR).
Austrian guidance for the pharmacologic treatment of osteoporosis in postmenopausal women: Addendum 2010].
Wien Med Wochenschr. 2010; 160(21-22):586-589
Doi: 10.1007/s10354-010-0840-z
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Dimai Hans Peter
- Co-Autor*innen der Med Uni Graz
- Dobnig Harald
- Fahrleitner-Pammer Astrid
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The Austrian Society for Bone and Mineral Research routinely publishes evidence-based guidelines for the treatment of postmenopausal osteoporosis. The fully human monoclonal antibody denosumab (Prolia(®)) has been recently approved by the European Medical Agency (EMEA) and the Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis. Denosumab has been shown to reduce vertebral, non-vertebral,and hip-fracture risk effectively. Together with alendronate, risedronate, zoledronate, ibandronate, strontium ranelate, and raloxifene, denosumab constitutes an effective option in the treatment of postmenopausal osteoporosis.
- Find related publications in this database (using NLM MeSH Indexing)
- Antibodies, Monoclonal - adverse effects
- Antibodies, Monoclonal, Humanized -
- Bone Density Conservation Agents - adverse effects
- Drug Approval -
- Drug Approval -
- Evidence-Based Medicine -
- Female -
- Fractures, Spontaneous - prevention & control
- Humans -
- Osteoporosis, Postmenopausal - drug therapy
- RANK Ligand - adverse effects